Theresa Stevens joins Lupin as Chief Corporate Development Officer

Theresa Stevens

Lupin announced the appointment of Theresa Stevens as Chief Corporate Development Officer for its global operations. Stevens will assume full responsibility for global merger and acquisitions and speciality business strategy. Prior to joining Lupin, she was with Aptalis pharma as the chief corporate development officer responsible for Mergers and Acquisitions (M&A), Strategy and Global Business Development.

Before Aptalis, Stevens was in Novartis for more than nine years and held positions of increasing responsibility including head, Global BD&L for General Medicines, executive director and head, Global BD&L for Respiratory and Dermatology Business Units and head US Business Development and Licensing, life cycle management and generic brand strategies.

She has a Masters Degree in Biochemistry from University of Maryland and is a Juris Doctor (J.D) from the Widener University School of Law, Wilmington, Delaware. She started her career as a research scientist at Dupont and has practiced Corporate Law at Pennie and Edmonds (Jones Day). Having worked with Aptalis and Novartis, Stevens has over 27 years of experience in the Pharmaceutical and Biotech sector with significant experience in managing strategy, corporate development, M&A and licensing.

EP News Bureau – Mumbai